The therapeutic potential of VLPs has also been tested in a CRC murine model using chimeric RHDV‐VLPs containing Topoisomerase IIα (topIIα) and/or survivin epitopes derived from CRC tumor‐associated antigens. The gene discussed is TOP2A; the disease is colorectal carcinoma.